Thor Medical ASA is a fast-growing scale-up enabling the next generation of targeted alpha therapies in oncology. We are building a fully funded, state-of-the-art production site, AlphaOne, and pioneering cutting-edge proprietary technology that eliminates the need for nuclear reactors and cyclotrons, making isotope production more efficient, sustainable, and accessible. By solving critical supply challenges of key isotopes for the pharmaceutical market, Thor Medical is unlocking a new generation of alpha-emitting radioligand therapies for millions of cancer patients worldwide. Thor Medical offers the opportunity to join an ambitious scale-up at the forefront of isotope production, contributing directly to its growth, success and impact in oncology innovation. The company is listed on the Oslo Stock Exchange under the ticker symbol TRMED.